| Methods |
Randomized
Multicenter |
| Participants |
Adults > 18 years old (mean age: 48)
CAP |
| Interventions |
Atypical: PO pristinamycin 1 G x 3
Non‐atypical: amoxacillin 1 G x 3 |
| Outcomes |
Clinical failure, bacteriological failure, pneumococcal treatment failure, mortality, s/e |
| Notes |
20% with COPD; 6.5% asthma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not identified |
| Allocation concealment (selection bias) |
Unclear risk |
Not identified |
| Incomplete outcome data (attrition bias)
Mortality |
High risk |
285/342 patients evaluated |
| Incomplete outcome data (attrition bias)
Failure |
High risk |
285/342 patients evaluated |
| Selective reporting (reporting bias) |
Low risk |
Not identified |
| Other bias |
Unclear risk |
sponsored by Pfizer Center Research |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
Double‐blind, double dummy |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Double‐blind |
